## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.4% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. CVS Stock Gains From Offering MMR Vaccine to South Carolina Residents**
- Source: TradingView â€” Track All Markets | 20251215T140828 | Bullish | Relevance: 100%
- CVS Health has seen its stock rise after announcing the offering of measles-mumps-rubella (MMR) vaccines to South Carolina residents following a recent outbreak. The initiative, provided through CVS Pharmacy stores and MinuteClinic locations, aims to protect against measles and is expected to further boost the company's stock performance. This move aligns with CVS's broader strategy to enhance consumer-centric healthcare and follows a strong segment revenue growth in Q3 2025.

**2. CVS Health Targets Steady Gains With A Revamped Game Plan**
- Source: Finimize | 20251210T180801 | Bullish | Relevance: 100%
- CVS Health has announced a new strategic plan aiming for steady, mid-teens earnings growth through 2028, driven by artificial intelligence and business streamlining. The company is focusing on higher-margin segments like Health Benefits and leveraging AI in its Health Services arm, which is gaining market confidence due to its stability in the turbulent healthcare sector. This strategy aligns with a broader industry trend of technology-driven growth, emphasizing data-driven approaches to improve patient experiences and control costs.

**3. National Bank of Canada FI Sells 83,710 Shares of CVS Health Corporation $CVS**
- Source: MarketBeat | 20251215T102514 | Bullish | Relevance: 100%
- National Bank of Canada FI recently decreased its stake in CVS Health Corporation by selling 83,710 shares, now holding 1,177,825 shares valued at $81.23 million. This comes as CVS Health shows strong financial performance, beating quarterly earnings expectations with $1.60 EPS and $102.87 billion in revenue, and offering a 3.3% dividend yield. Analysts maintain a "Moderate Buy" consensus with an average price target of $93.71, reflecting confidence in the company's outlook.

**4. TD Cowen Increases CVS Health (NYSE:CVS) Price Target to $105.00**
- Source: MarketBeat | 20251213T151412 | Bullish | Relevance: 100%
- TD Cowen has raised its price target for CVS Health (NYSE:CVS) to $105.00 from $100.00 and maintained a "buy" rating, indicating a potential 30.63% upside. Several other brokerages have also increased price targets or reiterated positive ratings following CVS's strong Q3 earnings beat and positive FY2025 guidance. CVS Health reported earnings of $1.60 per share on revenue of $102.87 billion, surpassing analyst expectations.

**5. CVS Health (NYSE: CVS) offers MMR vaccines in South Carolina amid measles outbreak**
- Source: Stock Titan | 20251211T160753 | Neutral | Relevance: 100%
- CVS Health (NYSE: CVS) is providing measles-mumps-rubella (MMR) vaccines at over 200 CVS Pharmacy and MinuteClinic locations across South Carolina to address a current measles outbreak. This initiative allows walk-ins, with appointments encouraged, and targets patients aged 3 and older, including a recommended second dose for children aged 4-6 at MinuteClinic. The company also announced an investor day event and positive financial guidance for 2025, highlighting its strategic initiatives alongside public health efforts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Bernstein | $87 | $86 | +1% |
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |
| 2025-12-10 | UBS | $97 | $96 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Bernstein | main | Market Perform |
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-12-10 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.56 indicates undervaluation relative to growth. Analyst sentiment positive (9 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $100.8B |
| Beta | 0.48 |
| 52W Range | $43.56 - $85.15 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.56 |
| Forward P/E | 11.1 |
| Current P/E | 11.9 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.8% to 1.4% (+5.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 2.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.45% (CS: 50) | Neutral |
| RSI_14 | 53.6 | Neutral |
| MACD Histogram | 0.26 | Bullish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.006x | Above |
| vs SMA200 | 1.134x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.42
- **Stop Loss:** $75.16 (5.4% risk)
- **Target:** $83.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 234
- **Position Value:** $18,584.28
- **Portfolio %:** 18.58%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*